120 related articles for article (PubMed ID: 38705879)
1. Differential analysis of histopathological and genetic markers of cancer aggressiveness, and survival difference in EBV-positive and EBV-negative prostate carcinoma.
Ahmed K; Sheikh A; Fatima S; Ghulam T; Haider G; Abbas F; Sarria-Santamera A; Ghias K; Mughal N; Abidi SH
Sci Rep; 2024 May; 14(1):10315. PubMed ID: 38705879
[TBL] [Abstract][Full Text] [Related]
2. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN.
Cai LM; Lyu XM; Luo WR; Cui XF; Ye YF; Yuan CC; Peng QX; Wu DH; Liu TF; Wang E; Marincola FM; Yao KT; Fang WY; Cai HB; Li X
Oncogene; 2015 Apr; 34(17):2156-66. PubMed ID: 25347742
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
4. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways.
Lin C; Zong J; Lin W; Wang M; Xu Y; Zhou R; Lin S; Guo Q; Chen H; Ye Y; Zhang B; Pan J
J Exp Clin Cancer Res; 2018 Nov; 37(1):283. PubMed ID: 30477559
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-encoded miR-BART11 promotes tumor-associated macrophage-induced epithelial-mesenchymal transition via targeting FOXP1 in gastric cancer.
Song Y; Li Q; Liao S; Zhong K; Jin Y; Zeng T
Virology; 2020 Sep; 548():6-16. PubMed ID: 32530809
[TBL] [Abstract][Full Text] [Related]
6. Assessing Performance and Clinical Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox Proportional Hazards Models.
McLernon DJ; Giardiello D; Van Calster B; Wynants L; van Geloven N; van Smeden M; Therneau T; Steyerberg EW;
Ann Intern Med; 2023 Jan; 176(1):105-114. PubMed ID: 36571841
[TBL] [Abstract][Full Text] [Related]
7. Targeting Cdc20 for cancer therapy.
Jeong SM; Bui QT; Kwak M; Lee JY; Lee PC
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188824. PubMed ID: 36243246
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.
Sekhoacha M; Riet K; Motloung P; Gumenku L; Adegoke A; Mashele S
Molecules; 2022 Sep; 27(17):. PubMed ID: 36080493
[TBL] [Abstract][Full Text] [Related]
9. The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications.
Yang L; Liu G; Li Y; Pan Y
Genes Dis; 2022 Sep; 9(5):1208-1219. PubMed ID: 35873027
[TBL] [Abstract][Full Text] [Related]
10. Correlation between Genomic Variants and Worldwide Epidemiology of Prostate Cancer.
Vieira GM; Gellen LPA; da Veiga Borges Leal DF; Pastana LF; Vinagre LWMS; Aquino VT; Fernandes MR; de Assumpção PP; Burbano RMR; Dos Santos SEB; Dos Santos NPC
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741800
[TBL] [Abstract][Full Text] [Related]
11. Detection and characterization of latency stage of EBV and histopathological analysis of prostatic adenocarcinoma tissues.
Ahmed K; Sheikh A; Fatima S; Haider G; Ghias K; Abbas F; Mughal N; Abidi SH
Sci Rep; 2022 Jun; 12(1):10399. PubMed ID: 35729214
[TBL] [Abstract][Full Text] [Related]
12. Multiple pathogens and prostate cancer.
Lawson JS; Glenn WK
Infect Agent Cancer; 2022 May; 17(1):23. PubMed ID: 35637508
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
